Beranda › Kanker Laring › Colorado › Colorado Springs
Uji klinis Kanker Laring di Colorado Springs, CO
3 studi untuk Kanker Laring mencari peserta di lokasi sekitar Colorado Springs (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Menerima pesertaFase 3
- UCHealth Memorial Hospital Central, Colorado Springs
- Memorial Hospital North, Colorado Springs
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Menerima pesertaFase 2
- UCHealth Memorial Hospital Central, Colorado Springs
- Memorial Hospital North, Colorado Springs
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Menerima pesertaFase 2
- Penrose-Saint Francis Healthcare, Colorado Springs
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs
- Saint Francis Cancer Center, Colorado Springs
Uji klinis Kanker Laring di kota lain
- Atlanta, GA8 studi
- Chicago, IL8 studi
- Milwaukee, WI8 studi
- Kansas City, MO7 studi
- Portland, OR7 studi
- St. Louis, MO7 studi
- Cincinnati, OH6 studi
- Richmond, VA6 studi
- Edison, NJ6 studi
- Baltimore, MD6 studi
- Pittsburgh, PA6 studi
- Durham, NC6 studi
Studi lain di Colorado Springs
- Kolitis Ulseratif14 studi
- Penyakit Crohn13 studi
- Kanker Prostat12 studi
- Kanker Paru Non-Sel Kecil11 studi
- Kanker Paru8 studi
- Kanker Payudara7 studi
- Asma6 studi
- Kanker Kolon6 studi
- Kanker Kolorektal6 studi
- Kanker Rektum4 studi
- Gangguan Somnolen Berlebih4 studi
- Penyakit Radang Usus4 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.